secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001558370-24-007060
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma Q1 operating loss $10.2M; secures $35M loan at 14% from Innoviva
------------------------------------------------------------------------------

- Grant revenue $1.0M (up from $0.8M YoY); R&D expense $8.0M (down from $9.6M); G&A $3.2M (up from $2.5M).
- Cash $37.9M as of March 31, 2024 vs $13.5M at Dec 31, 2023, aided by $35M credit agreement with Innoviva arm.
- Loan bears 14% annual interest, matures June 4, 2025; principal and interest payable at maturity.
- Phase 2a diSArm (AP-SA02) and Phase 2 Tail wind (AP-PA02) advancing; enrollment on track.
- cGMP manufacturing build-out expected mid-2024; R&D labs and admin space already operational.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837024007060/0001558370-24-007060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837024007060/armp-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer